The emergence of compounds like copyright and Semaglutide signifies a major shift in how we manage blood sugar. These innovative therapies belong to a class known as GLP-1 receptor agonists, which replicate the effects of a natural hormone that controls blood sugar levels and hunger. First, developed for diabetic conditions, their effectiveness in